January 30, 2025 10:23 AM ESTUpdated 10:46 AM
R&D

Tec­ton­ic gets Phase 1b win in heart con­di­tion where Eli Lil­ly re­cent­ly failed

Max Gelman

Senior Editor

A Phase 1b read­out in a spe­cif­ic heart con­di­tion is caus­ing an earth­quake for one new­ly pub­lic biotech.

Tec­ton­ic Ther­a­peu­tic on Thurs­day morn­ing

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Key GOP sen­a­tor is ‘strug­gling’ with Kennedy nom­i­na­tion over vac­cine an­swers

Car­go Ther­a­peu­tics cuts lead CAR-T pro­gram, 50% of staff

Take­da scraps pro­grams as it rais­es full-year guid­ance 

Roche aims for de­risked deals and ruth­less port­fo­lio cuts in 2025

Sanofi is in the mar­ket for M&A, thanks to ‘strong’ bal­ance sheet

sponsored

Why the pre­mier re­cruit­ment agency in the world is giv­ing up re­cruit­ing, and spon­sors should, too

A service from the Financial Times